Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Pierluigi Bonomo
Based on 2 articles published since 2010
(Why 2 articles?)
||||

Between 2010 and 2020, Pierluigi Bonomo wrote the following 2 articles about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Clinical Trial Quality of life and toxicity of stereotactic radiotherapy in pancreatic tumors: a case series. 2012

Macchia, Gabriella / Morganti, Alessio G / Cilla, Savino / Ippolito, Edy / Massaccesi, Mariangela / Picardi, Vincenzo / Mattiucci, Gian Carlo / Bonomo, Pierluigi / Tambaro, Rosa / Pacelli, Fabio / Piermattei, Angelo / De Spirito, Marco / Valentini, Vincenzo / Cellini, Numa / Deodato, Francesco. ·Radiotherapy Unit, Fondazione di Ricerca e Cura Giovanni Paolo II, Università-Cattolica, Campobasso, Italy. gmacchia@rm.unicatt.it ·Cancer Invest · Pubmed #22250589.

ABSTRACT: AIM: To analyze the results of extracranial stereotactic radiotherapy (ESRT) experience in pancreatic cancer patients. METHODS: Four noncoplanar fixed beams were used in all patients. RESULTS: Analysis of 16 patients was carried out. Overall response rate was 56.2%. Fifteen patients experienced local and/or distant progression of disease (median follow-up: 24 months). Two-year local progression-free, distant progression-free, and overall survivals were 85.7%, 58.7%, and 50.0%, respectively. Toxicity was less than grade 2 in all, although 1 patient had severe duodenal bleeding. Quality of life scores were unchanged. CONCLUSIONS: ESRT was associated with low complication rate, and not worsening the patients' quality of life.

2 Article Higher Biologically Effective Dose Predicts Survival in SBRT of Pancreatic Cancer: A Multicentric Analysis (PAULA-1). 2020

Arcelli, Alessandra / Guido, Alessandra / Buwenge, Milly / Simoni, Nicola / Mazzarotto, Renzo / Macchia, Gabriella / Deodato, Francesco / Cilla, Savino / Bonomo, Pierluigi / Scotti, Valerio / Belgioia, Liliana / Tolento, Giorgio / Cellini, Francesco / Grassi, Elisa / DI Marco, Mariacristina / Casadei, Riccardo / Morganti, Alessio G / Cammelli, Silvia. ·Radiation Oncology Center, Department of Experimental, Diagnostic and Specialty Medicine - DIMES, University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy. · Radiation Oncology Center, Department of Experimental, Diagnostic and Specialty Medicine - DIMES, University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy mbuwenge@gmail.com. · Radiotherapy Unit, Azienda Ospedaliera Universitaria, Verona, Italy. · Radiotherapy Unit, 'Giovanni Paolo II' Foundation, Catholic University of Sacred Heart, Campobasso, Italy. · Medical Physic Unit, 'Giovanni Paolo II' Foundation, Catholic University of Sacred Heart, Campobasso, Italy. · Radiation Oncology Unit, Department of Experimental and Clinical Biomedical Sciences, Azienda Ospedaliero-Universitaria Careggi (AOUC), University of Florence, Florence, Italy. · San Rossore Private Hospital, Pisa, Italy. · Department of Radiotherapy, Policlinico San Martino, University of Genoa, Genoa, Italy. · Fondazione Policlinico Universitario "A. Gemelli" IRCCS, UOC di Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Rome, Italy. · Oncology Unit, Department of Experimental, Diagnostic and Specialty Medicine - DIMES, University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy. · Department of Medical and Surgical Sciences - DIMEC, University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy. ·Anticancer Res · Pubmed #31892602.

ABSTRACT: AIM: The purpose of the present multicentric study was to review stereotactic body radiotherapy (SBRT) with or without chemotherapy (CHT) experience in locally advanced pancreatic cancer (LAPC). Endpoints were overall survival (OS), local control (LC), and distant metastasis-free survival (DMFS). Several parameters' impact on these outcomes was assessed. MATERIALS AND METHODS: Fifty-six patients with LAPC undergoing SBRT+/-CHT were included. SBRT median BED RESULTS: At a median follow-up of 15.0 months, 2-year OS, LC, DMFS were: 33.8% 55.4%, and 22.9%, respectively. Patients treated with BED CONCLUSION: SBRT proved to be tolerable and effective in LAPC. Moreover, BED